Home
ABUS
ABUS News

Latest Arbutus Biopharma Corporation (ABUS) News on April 3, 2025

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Zacks

3 days ago

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Zacks

3 days ago

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Novo gains Lexicon obesity drug; CRISPR COO to step down

BioPharma Dive

6 days ago

Novo gains Lexicon obesity drug; CRISPR COO to step down

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

Zacks

7 days ago

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

GlobeNewswire

7 days ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious

Barrons.com

8 days ago

As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious

MT Newswires

a month ago

Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

GlobeNewswire

a month ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

MT Newswires

a month ago

Arbutus Biopharma Names Lindsay Androski CEO, Overhauls Board

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

GlobeNewswire

a month ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy?

Insider Monkey

2 months ago

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy?

Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’

Insider Monkey

3 months ago

Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Zacks

3 months ago

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Arbutus Provides 2025 Corporate and Financial Update

GlobeNewswire

3 months ago

Arbutus Provides 2025 Corporate and Financial Update

Here’s Why Arbutus (ABUS) Surged in Q3

Insider Monkey

4 months ago

Here’s Why Arbutus (ABUS) Surged in Q3

Business Wire

4 months ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

GlobeNewswire

4 months ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

MT Newswires

5 months ago

Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

GlobeNewswire

5 months ago

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

GlobeNewswire

5 months ago

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Arbutus to Present at Jefferies London Healthcare Conference

GlobeNewswire

5 months ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...

GuruFocus.com

5 months ago

Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Arbutus Biopharma Corp Earnings Call

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Zacks

5 months ago

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

5 months ago

Arbutus: Q3 Earnings Snapshot

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

5 months ago

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire

5 months ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

GlobeNewswire

6 months ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

GlobeNewswire

6 months ago

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?

Zacks

6 months ago

Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?

Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?

Zacks

7 months ago

Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?

Arbutus to Participate in Two Upcoming Investor Conferences

GlobeNewswire

7 months ago

Arbutus to Participate in Two Upcoming Investor Conferences

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Zacks

7 months ago

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Zacks

8 months ago

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Thomson Reuters StreetEvents

8 months ago

Q2 2024 Arbutus Biopharma Corp Earnings Call

MT Newswires

8 months ago

Arbutus Biopharma to Reduce Workforce by 40% to Focus on Hepatitis B Treatment Imdusiran

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

Zacks

8 months ago

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

8 months ago

Arbutus: Q2 Earnings Snapshot

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

8 months ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire

9 months ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?

Zacks

10 months ago

Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?

MT Newswires

10 months ago

Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

GlobeNewswire

10 months ago

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

GlobeNewswire

10 months ago

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

GlobeNewswire

10 months ago

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus to Participate in Jefferies Global Healthcare Conference

GlobeNewswire

10 months ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

GlobeNewswire

10 months ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

MT Newswires

a year ago

Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program

MT Newswires

a year ago

Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program

Business Wire

a year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus to Participate in Two Upcoming Investor Conferences

GlobeNewswire

a year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript

Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

GuruFocus.com

a year ago

Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

GuruFocus.com

a year ago

Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

Zacks

a year ago

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

Associated Press Finance

a year ago

Arbutus: Q1 Earnings Snapshot

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

GlobeNewswire

a year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

Zacks

a year ago

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire

a year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

GlobeNewswire

a year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a year ago

Is Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans?

Arbutus to Participate in Two Upcoming Investor Conferences

GlobeNewswire

a year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

a year ago

Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts

Simply Wall St.

a year ago

Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q4 2023 Arbutus Biopharma Corp Earnings Call

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Zacks

a year ago

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials

GuruFocus.com

a year ago

Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

GlobeNewswire

a year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable

Simply Wall St.

a year ago

The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable

JOHN HANCOCK TAX-ADVANTAGED DIVIDEND INCOME FUND NOTICE TO SHAREHOLDERS - SOURCES OF DISTRIBUTION UNDER SECTION 19(a)

PR Newswire

a year ago

JOHN HANCOCK TAX-ADVANTAGED DIVIDEND INCOME FUND NOTICE TO SHAREHOLDERS - SOURCES OF DISTRIBUTION UNDER SECTION 19(a)

3 Growth Stocks Down Between 18.4% and 36.2% So Far This Year That Could Recover

Motley Fool

a year ago

3 Growth Stocks Down Between 18.4% and 36.2% So Far This Year That Could Recover

Old Second Bancorp, Inc. (NASDAQ:OSBC) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Old Second Bancorp, Inc. (NASDAQ:OSBC) Q4 2023 Earnings Call Transcript

Greenfire Resources Announces Operational Update, Including Strong Initial Refill Well Results and New WTI Hedging Program

Newsfile

a year ago

Greenfire Resources Announces Operational Update, Including Strong Initial Refill Well Results and New WTI Hedging Program

Spirit Airlines Dives Near Record Lows After JetBlue Warns On Merger Termination

Investor's Business Daily

a year ago

Spirit Airlines Dives Near Record Lows After JetBlue Warns On Merger Termination

Compared to Estimates, Old Second Bancorp (OSBC) Q4 Earnings: A Look at Key Metrics

Zacks

a year ago

Compared to Estimates, Old Second Bancorp (OSBC) Q4 Earnings: A Look at Key Metrics

What Is Energy Recovery, Inc.'s (NASDAQ:ERII) Share Price Doing?

Simply Wall St.

a year ago

What Is Energy Recovery, Inc.'s (NASDAQ:ERII) Share Price Doing?

Newmark Group's Fourth Quarter and Full Year 2023 Financial Results Announcement to be Issued Prior to Market Open on Thursday, February 22, 2024

PR Newswire

a year ago

Newmark Group's Fourth Quarter and Full Year 2023 Financial Results Announcement to be Issued Prior to Market Open on Thursday, February 22, 2024

Precious Metal Prices Trade Sideways After Short-Lived Rally

Oilprice.com

a year ago

Precious Metal Prices Trade Sideways After Short-Lived Rally

Title Resources Group Welcomes New Executive

PR Newswire

a year ago

Title Resources Group Welcomes New Executive

Why Dada Nexus Plunged and Took JD.com With It

Motley Fool

a year ago

Why Dada Nexus Plunged and Took JD.com With It

How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry

Zacks

a year ago

How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry

3 No-Brainer Stocks to Buy With $20 Right Now

Motley Fool

a year ago

3 No-Brainer Stocks to Buy With $20 Right Now

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

GlobeNewswire

a year ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Lindsay Corporation (NYSE:LNN) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Lindsay Corporation (NYSE:LNN) Q1 2024 Earnings Call Transcript

Insider Sell: Dynavax Technologies Corp President & COO David Novack Sells 9,000 Shares

GuruFocus.com

a year ago

Insider Sell: Dynavax Technologies Corp President & COO David Novack Sells 9,000 Shares

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update

Business Wire

a year ago

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update

Those who invested in CBIZ (NYSE:CBZ) five years ago are up 203%

Simply Wall St.

a year ago

Those who invested in CBIZ (NYSE:CBZ) five years ago are up 203%

JOHN HANCOCK CLOSED-END FUNDS DECLARE MONTHLY DISTRIBUTIONS

PR Newswire

a year ago

JOHN HANCOCK CLOSED-END FUNDS DECLARE MONTHLY DISTRIBUTIONS

Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company

Simply Wall St.

a year ago

Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company

Zhihu Inc.'s (NYSE:ZH) Intrinsic Value Is Potentially 55% Above Its Share Price

Simply Wall St.

a year ago

Zhihu Inc.'s (NYSE:ZH) Intrinsic Value Is Potentially 55% Above Its Share Price

4 Film & Television Production Stocks to Watch on Solid Industry Trends

Zacks

a year ago

4 Film & Television Production Stocks to Watch on Solid Industry Trends

Autolus Therapeutics Announces Changes to its Board of Directors

GlobeNewswire

a year ago

Autolus Therapeutics Announces Changes to its Board of Directors

Dril-Quip, Inc.'s (NYSE:DRQ) Share Price Matching Investor Opinion

Simply Wall St.

a year ago

Dril-Quip, Inc.'s (NYSE:DRQ) Share Price Matching Investor Opinion

BMO Optimistic About Fintech Stocks in 2024; Here Are 3 Top Picks to Keep an Eye On

TipRanks

a year ago

BMO Optimistic About Fintech Stocks in 2024; Here Are 3 Top Picks to Keep an Eye On

Sidoti Events, LLC's Virtual December Small-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

International Money Express (NASDAQ:IMXI) shareholders have earned a 12% CAGR over the last five years

Simply Wall St.

a year ago

International Money Express (NASDAQ:IMXI) shareholders have earned a 12% CAGR over the last five years

Share on Social Networks: